Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAPEUR: REZŪM vs Dual Drug Therapy for BPH
NCT04838769Active, not recruiting
- Sponsor
- Boston Scientific Corporation
- Start
- Sep 2021
- Primary completion
- Dec 2025
- Countries
- 2
01
Overview
Randomised, open-label trial in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Boston Scientific Corporation. Primary endpoints: International Prostate Symptom Score at 12 months and Male Sexual Health Questionnaire at 12 months. Started Sep 2021; status: active, not recruiting.
02
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT04838769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838769.